SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults

Matthew E Levy; Evanette Burrows; Vanessa Chilunda; Pamala A Pawloski; Phillip R Heaton; Joseph Grzymski; Jason D Goldman; Lisa M McEwen; Dana Wyman; Andrew Dei Rossi; Hang Dai; Magnus Isaksson; Nicole L Washington; Tracy Basler; Kevin Tsan; Jason Nguyen; Jimmy Ramirez; Efren Sandoval; William Lee; James Lu; Shishi Luo

doi:10.1093/cid/ciad796

SARS-CoV-2 Antiviral Prescribing Gaps Among Non-Hospitalized High-Risk Adults

Clin Infect Dis. 2024 Jan 3:ciad796. doi: 10.1093/cid/ciad796. Online ahead of print.

Authors

Matthew E Levy¹, Evanette Burrows¹, Vanessa Chilunda¹, Pamala A Pawloski², Phillip R Heaton³, Joseph Grzymski^{4

5}, Jason D Goldman^{6

7

8}, Lisa M McEwen¹, Dana Wyman¹, Andrew Dei Rossi¹, Hang Dai¹, Magnus Isaksson¹, Nicole L Washington¹, Tracy Basler¹, Kevin Tsan¹, Jason Nguyen¹, Jimmy Ramirez¹, Efren Sandoval¹, William Lee¹, James Lu¹, Shishi Luo¹

Affiliations

¹ Helix, San Mateo, California, USA.
² HealthPartners Institute, Minneapolis, Minnesota, USA.
³ Department of Pathology and Laboratory Medicine, HealthPartners, Bloomington, Minnesota, USA.
⁴ Department of Internal Medicine, University of Nevada Reno, School of Medicine, Reno, Nevada, USA.
⁵ Renown Health, Reno, Nevada, USA.
⁶ Providence St. Joseph Health System, Renton, Washington, USA.
⁷ Swedish Center for Research and Innovation, Swedish Medical Center, Seattle, Washington, USA.
⁸ Division of Infectious Disease, University of Washington, Seattle, Washington, USA.

PMID: 38170452
DOI: 10.1093/cid/ciad796

Abstract

Within a multi-state clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among non-hospitalized SARS-CoV-2-infected patients with risk factors for severe COVID-19. Among 3,247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

Keywords: Sars-CoV-2; antiviral agents; electronic health records; molnupiravir; nirmatrelvir.